Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Day One Biopharmaceuticals Inc (DAWN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: DAWN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -39.47% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 817.93M USD | Price to earnings Ratio - | 1Y Target Price 31.12 |
Price to earnings Ratio - | 1Y Target Price 31.12 | ||
Volume (30-day avg) 1355787 | Beta -1.39 | 52 Weeks Range 7.51 - 18.07 | Updated Date 04/1/2025 |
52 Weeks Range 7.51 - 18.07 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -72.81% | Operating Margin (TTM) -223.68% |
Management Effectiveness
Return on Assets (TTM) -27.67% | Return on Equity (TTM) -22.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 274623311 | Price to Sales(TTM) 6.24 |
Enterprise Value 274623311 | Price to Sales(TTM) 6.24 | ||
Enterprise Value to Revenue 2.09 | Enterprise Value to EBITDA -7.18 | Shares Outstanding 101355000 | Shares Floating 71972855 |
Shares Outstanding 101355000 | Shares Floating 71972855 | ||
Percent Insiders 16.96 | Percent Institutions 94.6 |
Analyst Ratings
Rating 4.3 | Target Price 36.11 | Buy 5 | Strong Buy 4 |
Buy 5 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Day One Biopharmaceuticals Inc
Company Overview
History and Background
Day One Biopharmaceuticals, founded in 2018, focuses on developing and commercializing targeted therapies for pediatric cancer. They aim to address unmet needs in this area, particularly for genetically defined cancers. Their initial focus is on a lead asset for pediatric low-grade glioma.
Core Business Areas
- Oncology Drug Development: Focuses on research, development, and commercialization of targeted therapies for pediatric cancers. This includes identifying promising drug candidates, conducting clinical trials, and securing regulatory approvals.
Leadership and Structure
Day One's leadership team includes seasoned professionals with experience in pharmaceutical development and commercialization. The organizational structure is designed to support efficient drug development and strategic partnerships.
Top Products and Market Share
Key Offerings
- Tovorafenib (DAY101): Tovorafenib is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor, which is used in the treatment for relapsed or progressive pediatric low-grade glioma (pLGG). It is currently in clinical trials, with potential for FDA approval. Competitors include drugs used off-label and other emerging targeted therapies.
Market Dynamics
Industry Overview
The oncology drug market is rapidly evolving, with increasing focus on targeted therapies and precision medicine. There is a significant unmet need for effective treatments for pediatric cancers.
Positioning
Day One is positioned as a company focused on developing innovative targeted therapies for pediatric cancers. Their competitive advantage lies in their focus on genetically defined cancers and their lead asset, Tovorafenib.
Total Addressable Market (TAM)
The TAM for pediatric oncology is substantial, with estimates varying based on cancer type and treatment modality. Day One is positioned to capture a share of this market with successful development and commercialization of their therapies.
Upturn SWOT Analysis
Strengths
- Focus on unmet need in pediatric oncology
- Lead asset with promising clinical data
- Experienced leadership team
- Targeted approach to drug development
Weaknesses
- Reliance on single lead asset
- Limited commercial infrastructure
- Limited established sales network
- Relatively young company
Opportunities
- Potential for regulatory approval of Tovorafenib
- Expansion of pipeline through acquisitions or partnerships
- Advancements in precision medicine and diagnostics
- Growing awareness of pediatric cancer needs
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- MRTX
- LLY
- NVS
Competitive Landscape
Day One competes with established pharmaceutical companies and other biotechnology companies developing therapies for pediatric cancer. Their competitive advantage lies in their focus on targeted therapies and their lead asset, Tovorafenib. However, at this point it does not have a product on the market, so it has no sales to establish market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Day One's historical growth is reflected in its progress in advancing Tovorafenib through clinical trials and securing funding.
Future Projections: Future growth projections are dependent on the successful development and commercialization of Tovorafenib and other pipeline candidates.
Recent Initiatives: Recent initiatives include advancing Tovorafenib through clinical trials and exploring potential partnerships and acquisitions.
Summary
Day One Biopharmaceuticals is a pre-commercialization stage company focused on pediatric oncology. Their strength lies in their targeted approach and promising lead asset, Tovorafenib. Challenges include reliance on a single asset and competition from larger pharmaceutical companies. Securing regulatory approval and commercialization success are crucial for future growth.
Similar Companies
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Day One Biopharmaceuticals Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-27 | CEO, President & Director Dr. Jeremy Bender M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://dayonebio.com |
Full time employees 181 | Website https://dayonebio.com | ||
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.